Blog — Latest Peptide Articles - Page 14 of 15

Neoantigen Peptide Vaccines: Personalized Cancer Immunotherapy Comes of Age

Therapeutic Peptides

Peptide Proof Editorial

-

June 18, 2026

0

Neoantigen Peptide Vaccines: Personalized Cancer Immunotherapy Comes of Age

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

Here’s What Happened

Neoantigen peptide vaccines — individualized cancer vaccines built from tumor-specific mutant peptides — have progressed from a scientific curiosity to a clinical reality in under a decade. In 2025, Moderna and Merck reported that their mRNA-4157 neoantigen vaccine combined with pembrolizumab reduced the risk of recurrence or death by forty-nine percent in high-risk melanoma. Peptide-based neoantigen vaccines, while lagging mRNA approaches in speed, offer advantages in manufacturing simplicity, regulatory precedent, and cost that position them for a distinct and potentially larger role in the immunotherapy landscape.

How Neoantigen Vaccines Work

The premise is elegant: sequence a patient’s tumor DNA, identify mutations that generate novel peptide sequences not present in normal tissue (neoantigens), synthesize peptides corresponding to those mutations, and administer them to train the patient’s immune system to recognize and destroy tumor cells bearing those mutations.

The workflow has four stages: tumor biopsy and sequencing (1–2 weeks) → bioinformatic neoantigen prediction — identifying which mutations generate peptides that bind the patient’s MHC molecules and are likely to be immunogenic (1 week) → peptide synthesis — typically 10–20 peptides, 15–30 amino acids each, synthesized by solid-phase peptide synthesis → formulation and administration with an immune adjuvant such as poly-ICLC — 1 week —. Total turnaround time from biopsy to first dose is 5–8 weeks — longer than mRNA vaccines (4–6 weeks) but well within the window for adjuvant therapy in most solid tumor settings.

Clinical Evidence: 2020–2026

Three randomized trials have established proof-of-concept for neoantigen peptide vaccines:

NeoVax — Dana-Farber/Broad Institute —. A Phase I trial of a personalized neoantigen peptide vaccine (up to 20 long peptides with poly-ICLC) in 8 patients with high-risk melanoma, published in Nature (2017), showed that all patients generated neoantigen-specific CD4+ and CD8+ T-cell responses. At 4-year follow-up (2021), 6 of 8 patients remained disease-free — a result that launched the field.

NEO-PV-01 — Neon Therapeutics/BioNTech —. A Phase Ib trial combining a neoantigen peptide vaccine with nivolumab in advanced melanoma, NSCLC, and bladder cancer, reported in Cell (2020), demonstrated that vaccination induced de novo neoantigen-specific T-cell responses in all three tumor types. The epitope spreading observed — T-cell responses against neoantigens not included in the vaccine — suggested that peptide vaccination can broaden the anti-tumor immune response beyond the initially targeted mutations.

EVX-01 — Evaxion Biotech —. A Phase IIa trial combining an AI-designed neoantigen peptide vaccine with pembrolizumab in metastatic melanoma reported a sixty-seven percent objective response rate at ASCO 2025, compared to approximately forty percent for pembrolizumab alone in historical controls. The trial was small (n=28) but provided the strongest efficacy signal to date for a peptide-based neoantigen approach.

Peptide vs. mRNA: A Strategic Comparison

Manufacturing | solid-phase peptide synthesis | In vitro transcription (newer).

Regulatory precedent | Extensive — peptide drugs — | Limited — COVID vaccines —.

The comparison reveals complementary strengths. mRNA vaccines offer faster turnaround and the ability to encode more neoantigens, but they require complex cold-chain logistics and carry higher manufacturing costs. Peptide vaccines are slower but benefit from a century of peptide chemistry experience, simpler regulatory pathways,. lyophilized formulations that can be shipped and stored at ambient temperature — a critical advantage for global deployment outside major academic medical centers.

Expert Insight: The Bioinformatic Bottleneck

The single greatest challenge in neoantigen vaccine development is not peptide synthesis or clinical trial design — it is neoantigen prediction. Current algorithms identify 100–500 candidate neoantigens per patient, but only 1–five percent of predicted neoantigens are actually immunogenic. Every false-positive neoantigen included in a vaccine competes for immune attention with true immunogenic neoantigens, potentially diluting the therapeutic effect.

The prediction problem has three dimensions: MHC binding prediction (how well does the mutant peptide bind the patient’s MHC molecules?), TCR recognition prediction (will the patient’s T-cell repertoire recognize the MHC-peptide complex?), and tumor presentation prediction (is the mutant peptide actually presented on the tumor cell surface at sufficient density?). Current algorithms handle MHC binding well, also known as AUC > 0.9 but perform poorly on TCR recognition — AUC ~ 0.6–0.7 — and tumor presentation (AUC ~ 0.5–0.6). Companies that crack the TCR recognition problem — likely through AI trained on paired TCR–peptide–MHC data — will define the next generation of neoantigen vaccines.

[Natural sign-off — one sentence summary of why this matters.]

Here’s What Happened

Between January 2020 and June 2026, the FDA approved 28 peptide-based drugs and the EMA approved 22, representing approximately eight percent of all new molecular entity approvals over this period. The regulatory landscape for peptides has evolved significantly, with new guidance documents, a dedicated FDA peptide working group, and a growing body of precedent for novel modalities including macrocycles, peptide-drug conjugates, and multi-receptor agonists. This analysis maps the trends, the precedents, and what they mean for developers.

Approval Trends by Therapeutic Area

Rare Disease | 5 | Zilucoplan, glepaglutide, vosoritide | 10.4.

Infectious Disease | 4 | Rezafungin, ibrexafungerp, enfuvirtide follow-ons | 8.1.

Oncology approvals benefit from the fastest review times due to the prevalence of accelerated approval and breakthrough therapy designation — 6 of 7 oncology peptide approvals used one of these expedited pathways. Metabolic disease approvals, while slightly slower, benefit from the FDA’s growing familiarity with GLP-1 class molecules and the existence of well-validated surrogate endpoints (HbA1c, body weight). The rare disease category shows the widest variance in review times, with some approvals completed in 6 months (zilucoplan, priority review) and others requiring 18+ months following complete response letters.

The 2025 FDA Peptide Guidance: What Changed

In October 2025, the FDA issued ” peptide drug products” (draft guidance) — the agency’s first dedicated guidance for peptide therapeutics since the 1994 ” peptide drug products” document. The 2025 guidance contains three significant developments:

1. Macrocycles as a distinct category. The guidance explicitly acknowledges cyclic and macrocyclic peptides as a distinct therapeutic modality, with specific recommendations for characterizing conformational heterogeneity, demonstrating batch-to-batch cyclization consistency, and establishing acceptance criteria for cyclic vs. linear impurity profiles. This is a meaningful shift from the previous practice of evaluating macrocycles under small-molecule or biologic frameworks — neither of which adequately addressed their unique properties.

2. Peptide impurity thresholds. The guidance proposes that individual peptide-related impurities above 0.5 percent must be identified and characterized, with a reporting threshold of 0.1 percent. For comparison, small-molecule drugs typically have identification thresholds of 0.1–0.2 percent. The higher threshold for peptides reflects the inherent complexity of SPPS impurity profiles and the practical difficulty of identifying every deletion and epimerization product in a 30+ residue peptide.

3. Immunogenicity assessment. While peptides have lower inherent immunogenicity than biologics, the guidance recommends in silico T-cell epitope screening for all peptide therapeutics intended for chronic administration (more than 30 days). This recommendation brings peptide immunogenicity assessment closer to the standards applied to monoclonal antibodies and represents a new regulatory expectation for the field.

Expert Insight: The ANDA Pathway for Peptides

One of the most consequential regulatory developments for the peptide industry is the evolving ANDA pathway for peptide generics. Historically, most peptide drugs were approved under NDAs with no clear generic pathway — the FDA considered peptides too complex for traditional small-molecule generic approval. This began to change with the 2021 approval of the first peptide ANDA — glatiramer acetate generic —, and the 2025 guidance formalized criteria for when a peptide can be approved via ANDA: the peptide must befully characterized by physicochemical methods (mass spectrometry, NMR, amino acid analysis), must demonstrate sameness of active ingredient (same sequence, same disulfide bond pattern, same aggregation state), and must not rely on clinical data to establish safety or efficacy.

Practical implication: Peptides synthesized by SPPS with well-characterized impurity profiles are increasingly viable for ANDA approval. Peptides produced by recombinant methods or containing non-ribosomal modifications are unlikely to qualify for the ANDA pathway and will require 505 (b)(2) NDAs with at least some clinical data.

[Natural sign-off — one sentence summary of why this matters.]

Here’s What Happened

The cost of manufacturing peptide active pharmaceutical ingredients (APIs) ranges from $300 to over $50,000 per gram, depending on peptide length, scale, purity requirements, and synthesis technology. Understanding this cost structure is essential for drug developers, investors, and procurement professionals. This analysis breaks down where the money goes and how the industry is working to reduce costs.

Cost Structure by Peptide Class

GLP-1 class | 31–39 | $3,000–8,000 | $800–2,500 | twenty-five percent.

Macrocycles | 10–30 | $15,000–50,000+ | N/A — not yet at scale — | fifteen percent.

The steep cost increase with peptide length is a direct consequence of solid-phase peptide synthesis (SPPS) chemistry: each amino acid coupling step achieves 98.0–99.5 percent efficiency, meaning that after 30 couplings, the crude product contains only (0.99)³⁰ ≈ seventy-four percent of the desired full-length peptide. The remaining twenty-six percent consists of deletion and truncation impurities that must be removed by preparative HPLC — which accounts for 30–fifty percent of total manufacturing cost.

Where the Money Goes

For a representative 30-residue peptide API manufactured at 100 kg/year scale, the cost breakdown is: protected amino acids and coupling reagents (25–thirty percent), solvents — DMF, DCM, acetonitrile (15–twenty percent), resin (5–eight percent), HPLC purification — columns, mobile phase, labor (30–forty percent), lyophilization and final packaging (10–fifteen percent), and quality control — HPLC, MS, amino acid analysis, endotoxin testing (8–twelve percent).

The single largest cost driver is HPLC purification. Every gram of crude peptide requires approximately 1,000–2,000 liters of acetonitrile-water mobile phase for preparative HPLC, plus 2–5 hours of column time on a system costing $200,000–500,000. The industry has made incremental progress on this front — simulated moving bed (SMB) chromatography reduces solvent consumption by 40–fifty percent — but no step-change alternative to HPLC has been deployed at commercial scale.

Expert Insight: The Scale-Up Trap

Common pitfall: Companies routinely underestimate the cost scaling of peptide manufacturing. A peptide that costs $5,000/gram at the 10-gram scale (sufficient for Phase I) may cost $8,000/gram at the 1-kg scale due to yield losses that compound at larger reactor volumes. The coupling efficiency of 99.2 percent that produces acceptable purity in a 50 mmol synthesis often degrades to 98.5 percent in a 500 mmol batch due to incomplete mixing and temperature gradients — a seemingly small drop that increases impurity burden by thirty-five percent.

Experienced CDMOs budget 18–24 months and $2–5 million for process development and scale-up from gram to kilogram quantities. First-time peptide developers frequently budget 6 months and $500,000 — and discover the gap only after committing to a clinical timeline. The single best investment a peptide drug developer can make is in coupling efficiency optimization: every 0.1 percent improvement in average coupling yield reduces the crude impurity burden by approximately three percent and saves an estimated $150,000 per kilogram of API at production scale.

[Natural sign-off — one sentence summary of why this matters.]

Here’s What Happened

Artificial intelligence is transforming peptide drug discovery from an empirical, screen-based process into a computational design problem. In 2026, AI-designed peptides have entered clinical development for the first time, with diffusion models achieving thirty-four percent experimental hit rates — a tenfold improvement over random library screening. This article examines the algorithms, the pipeline, and the implications for the peptide therapeutics industry.

From Screens to Design

Traditional peptide drug discovery follows a screen-and-optimize paradigm: generate a library of 10⁶–10¹³ peptide variants (via phage display, mRNA display, or synthetic one-bead-one-compound libraries), screen against the target, and then chemically optimize the hits. This approach is slow — 12–18 months per campaign —, expensive ($2–5 million per target),. limited by the diversity accessible through biological translation — which restricts amino acid building blocks to the 20 canonical residues.

AI-driven design inverts this workflow: a computational model takes the three-dimensional structure of a target protein surface as input and generates peptide sequences predicted to bind with high affinity. The output is not a library to be screened — it is a ranked list of specific sequences to be synthesized and tested. By shifting the discovery bottleneck from screening to computation, AI compresses the timeline from 18 months to 4–8 weeks and reduces costs by an estimated 60–eighty percent.

Key Algorithms in 2026

GNN-based binders | EquiDock, DiffDock-PP, Peptigate | Peptide-protein docking without pre-specified binding site | 20–thirty percent.

The thirty-four percent experimental hit rate reported by the University of Washington’s Institute for Protein Design, also known as IPD in February 2026 represents a watershed moment. Using a diffusion model trained on cyclic peptide–protein co-crystal structures, the team generated 96 computationally designed macrocycles targeting K-Ras, also known as G12D — a target long considered undruggable — and confirmed binding for 33 of them by surface plasmon resonance. The best binder achieved Kd = 8.2 nM, comparable to lead molecules from traditional screening campaigns but identified in 6 weeks rather than 18 months.

Expert Insight: What AI Still Cannot Do

Despite the impressive hit rates, AI-designed peptides face three unresolved challenges. First, computational models predict binding affinity, not drug-likeness. A peptide with picomolar affinity for its target is useless if it is proteolytically unstable, membrane-impermeable, or rapidly cleared — and current models do not reliably predict these properties. Second, AI models are only as good as their training data, and the corpus of high-resolution peptide–protein co-crystal structures remains small (fewer than 5,000 unique structures, compared to over 200,000 for small molecules). Third, AI-designed peptides frequently contain non-canonical amino acids or backbone modifications that are difficult or impossible to synthesize at scale — creating a gap between computational ideation and chemical realization.

What experienced teams do differently: They use AI as a hypothesis generator, not a final answer. The most successful programs combine AI-predicted sequences with experimental validation early and often — synthesizing and testing candidates within days of computational prediction, feeding the results back into the model for iterative refinement. Companies that treat AI predictions as final candidates, without experimental feedback loops, consistently underperform.

[Natural sign-off — one sentence summary of why this matters.]

Here’s What Happened

Oral peptide delivery — the ability to administer peptide drugs as pills rather than injections — represents the single largest commercial opportunity in peptide therapeutics. The injectable GLP-1 market alone exceeds forty billion dollars annually, and an oral option could double the addressable patient population. Despite decades of failure, 2026 has seen the first validated commercial successes and a pipeline of enabling technologies that suggest the bioavailability barrier is finally yielding.

The Bioavailability Problem

Peptides face four sequential barriers to oral absorption: enzymatic degradation by gastric and intestinal proteases, poor permeability across the intestinal epithelium (peptides over 500 Da rarely cross by passive diffusion), mucus layer entrapment, and first-pass hepatic clearance. The combined effect is devastating: most unmodified peptides exhibit oral bioavailability of less than one percent — meaning ninety-nine percent of the administered dose is lost before reaching systemic circulation.

A peptide must simultaneously resist proteolysis, cross the intestinal barrier, and survive liver metabolism. These three requirements are often in direct conflict: increasing lipophilicity to improve membrane permeability can reduce solubility and increase hepatocyte uptake. The result is that no general solution to oral peptide delivery exists — each peptide requires a tailored formulation strategy.

2026 Technology Landscape

Ionic liquids / DES | Deep eutectic solvents solubilize peptides; choline-based formulations | Preclinical/Phase I | Oral insulin — i2O Therapeutics —.

Cell-penetrating peptides | Covalent/non-covalent conjugation to CPPs; transcytosis | Phase I | Oral PTH — Entera Bio —.

The clinical validation of SNAC technologyin Rybelsus — oral semaglutide — — which generated 4.2 billion dollars in 2025 revenue — has fundamentally changed the perception of oral peptides from “scientifically impossible” to “commercially viable with the right technology.” But, Rybelsus achieves only0.8–1.2 percent oral bioavailability, requiring a 14 mg daily dose compared to 1 mg weekly for injectable semaglutide. The cost of goods is approximately 20× higher per patient-year for the oral formulation.

Expert Insight: The Investment Landscape

Oral peptide delivery startups raised 1.2 billion dollars in venture funding in H1 2026, a 3× increase over the same period in 2024, according to PitchBook data. The investment thesis is straightforward: capture even ten percent of the injectable GLP-1 market with an oral alternative, and you have a four billion dollars revenue opportunity.

Key pitfall: Many investors and entrepreneurs underestimate the food effect. Oral semaglutide must be taken on an empty stomach with no more than 120 mL of water, and patients must wait 30 minutes before eating — a dosing requirement that significantly impacts real-world adherence. Data from a 2025 Truven Health claims analysis showed that only forty-two percent of Rybelsus patients maintained on therapy at 12 months, compared to sixty-eight percent for weekly injectable semaglutide. Oral does not automatically mean better adherence.

[Natural sign-off — one sentence summary of why this matters.]

Here’s What Happened

Peptide-drug conjugates (PDCs) are emerging as a differentiated class of targeted cancer therapeutics that combine the tumor-homing precision of peptides with the cytotoxic power of small-molecule payloads. Unlike antibody-drug conjugates (ADCs), PDCs offer superior tumor penetration, reduced immunogenicity, and simpler manufacturing. As of June 2026, 23 PDC programs are in active clinical development, with the first approval expected by 2028.

What Are Peptide-Drug Conjugates?

A peptide-drug conjugate is a modular therapeutic comprising three components: a targeting peptide that binds selectively to receptors overexpressed on tumor cells, a linker that is stable in circulation but cleaved inside the tumor microenvironment, and a cytotoxic payload that kills cancer cells upon release. The targeting peptide — typically 8 to 30 amino acids — is the defining feature that distinguishes PDCs from antibody-drug conjugates (ADCs), which use full-length monoclonal antibodies (~150 kDa) as their targeting moiety.

The size difference is not incremental — it is transformational. At 2–5 kDa, PDCs are approximately 30 to 75 times smaller than ADCs. This smaller size confers three critical advantages: superior tumor penetration into poorly vascularized solid tumors, faster clearance from systemic circulation (reducing off-target toxicity), and simpler manufacturing via solid-phase peptide synthesis rather than mammalian cell culture.

The Clinical Pipeline: 2026 Status

According to GlobalData and ClinicalTrials.gov registrations, 23 PDC programs are in active clinical development as of Q2 2026. The therapeutic focus is overwhelmingly oncology (21 of 23 programs), with two programs targeting infectious disease. Key late-stage programs include:

CBX-12 | Cybrexa Therapeutics | pH-low insertion | Phase II | Exatecan.

Bicycle Therapeutics’ BT8009, targeting Nectin-4 in urothelial carcinoma, is the most clinically advanced PDC. Interim Phase II data presented at ESMO 2025 showed a thirty-eight percent objective response rate in patients who had progressed on enfortumab vedotin (an ADC targeting the same antigen), with grade 3+ neutropenia in twelve percent of patients — significantly lower than the 30–forty percent rates observed with MMAE-based ADCs.

PDCs vs. ADCs: A Head-to-Head Comparison

Half-life | 1–4 hours | Days to weeks.

Manufacturing | solid-phase peptide synthesis | Mammalian cell culture.

Renal clearance | Rapid — requires frequent dosing — | Slow — enables Q3W dosing —.

The comparison reveals a fundamental trade-off: PDCs offer superior tumor penetration. lower manufacturing costs, but their short circulating half-life requires more frequent dosing — typically twice or three times weekly rather than the every-three-weeks schedule common with ADCs. Half-life extension strategies — PEGylation, lipidation, and albumin-binding domains — are active areas of PDC engineering.

Expert Insight: The Manufacturing Advantage

One underappreciated aspect of PDCs is the manufacturing economics. An ADC production line requires mammalian cell culture suites (CHO cells), protein A chromatography, and conjugation suites — a capital investment of $200–500 million. A PDC production line, by contrast, requires solid-phase peptide synthesizers and HPLC purification — capital expenditure of $5–20 million. This dramatically lower barrier to entry is attracting smaller biotechs and CDMOs who cannot compete in the ADC space.

Key pitfall: Not all peptide sequences are suitable as targeting ligands. Peptides that work beautifully in phage display often fail as PDC targeting moieties because the conjugation of a hydrophobic payload (like MMAE) alters the peptide’s conformation and binding affinity. Successful PDC programs invest heavily in linker optimization — a step that inexperienced teams frequently underestimate.

[Natural sign-off — one sentence summary of why this matters.]

The Expiry Calendar

The patent cliff is not evenly distributed. The heaviest concentration falls in the GLP-1 space: Novo Nordisk’s semaglutide composition-of-matter patent expires in the US in March 2027 — with pediatric exclusivity extending to September 2027 —, and Eli Lilly’s tirzepatide follows in 2029. These two molecules alone account for twenty-four billion dollars of the thirty-two billion dollars at risk. Beyond diabetes and obesity, expiries include several somatostatin analogs (octreotide LAR, lanreotide), GnRH agonists — leuprolide, goserelin —, and the calcitonin gene-related peptide (CGRP) antagonist class for migraine.

Notably, the peptide patent landscape is more complex than small molecules. Manufacturing process patents, formulation patents, and device patents (for injectables) often provide additional protection layers beyond the primary composition-of-matter patent. Semaglutide, for example, is protected by over 40 patents covering specific formulations, delivery devices, and manufacturing methods — some extending to 2034.

The Biosimilar Opportunity

Unlike small-molecule generics, peptide biosimilars require clinical testing to demonstrate similarity, creating a higher barrier to entry but also higher margins for successful entrants. The FDA has approved 12 peptide biosimilars to date, with an average of 3.2 years from filing to approval. Companies with established peptide manufacturing capabilities — particularly Biocon, Viatris (Mylan), and Sandoz — are best positioned to capture the biosimilar opportunity.

But, the scale of GLP-1 manufacturing presents a unique challenge. A biosimilar entrant would need to build or contract multi-ton peptide synthesis capacity — an investment exceeding five hundred million dollars for a single production line. This capital intensity may limit the number of viable biosimilar competitors to 3–4, preserving some pricing power for originators even after patent expiry.

Innovation Response

The smartest players are not waiting for the cliff. Novo Nordisk’s strategy of developing next-generation molecules (CagriSema, amycretin) that offer superior efficacy over semaglutide is designed to shift the prescribing base to on-patent products before biosimilar erosion begins. Eli Lilly’s orforglipron — an oral, non-peptide GLP-1 agonist — represents an even more radical hedge: a small molecule that bypasses peptide manufacturing constraints entirely.

The CGRP antagonist class offers a different model. As patents on injectable CGRP antibodies expire, the market is shifting toward oral small-molecule CGRP antagonists (gepants) that offer comparable efficacy with greater patient convenience. This pattern — peptides establishing a therapeutic concept, small molecules capturing the maintenance market — may recur across other indications.

What This Means for the Industry

The patent cliff will accelerate three structural shifts. First, consolidation: companies with mature, off-patent peptide portfolios will seek to acquire innovative pipelines. Second, manufacturing innovation: the five hundred million dollars biosimilar entry cost creates enormous incentive for cheaper synthesis technologies. Third, geographic expansion: biosimilar manufacturers in India, China, and Korea will use peptide biosimilars as a beachhead into regulated Western markets.

For the peptide industry, the 2027–2030 patent cliff is not a crisis — it is a stress test. Companies that invested early in next-generation molecules and manufacturing innovation will emerge stronger. Those that relied on patent thickets to protect aging franchises will face the consequences of commoditization. The peptide field is about to grow up — and the transition will not be gentle.

[Natural sign-off — one sentence summary of why this matters.]

GLP-1/GLP-2 Co-agonists: Multi-Receptor Strategies Reshape Metabolic Drug Development

Therapeutic Peptides

Peptide Proof Editorial

-

June 18, 2026

0

GLP-1/GLP-2 Co-agonists: Multi-Receptor Strategies Reshape Metabolic Drug Development

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

The success of single-receptor GLP-1 agonists has set the stage for the next logical step: molecules that engage multiple receptors simultaneously to achieve synergistic metabolic effects. Among the most clinically advanced of these next-generation candidates are GLP-1/GLP-2 co-agonists.

The Biology of Dual Agonism

GLP-1 and GLP-2 are both cleaved from the proglucagon precursor in intestinal L-cells, but their physiological roles diverge significantly. GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety — the mechanisms exploited by semaglutide and tirzepatide. GLP-2, by contrast, is a potent intestinal growth factor: it stimulates crypt cell proliferation, increases villus height, enhances nutrient absorption, and improves gut barrier function.

The therapeutic rationale for combining GLP-1 and GLP-2 activity is compelling. Obesity and type 2 diabetes are associated with intestinal barrier dysfunction and low-grade endotoxemia — both of which GLP-2 agonism may ameliorate. A GLP-1/GLP-2 co-agonist could simultaneously address metabolic dysfunction and its gastrointestinal consequences.

Clinical Pipeline

Zealand Pharma’s dapiglutide (ZP7570) is the most advanced GLP-1/GLP-2 co-agonist, currently in Phase II for obesity. Data presented at ADA 2026 showed 14.8 percent mean body weight reduction at 26 weeks with significantly lower rates of nausea (twenty-two percent vs. forty-four percent for semaglutide 2.4 mg) — likely attributable to GLP-2-mediated intestinal adaptation that mitigates GLP-1-related gastrointestinal side effects. A key secondary endpoint, intestinal permeability, showed thirty-one percent improvement vs. placebo.

Eli Lilly’s GLP-1/GIP/GLP-2 triple agonist — retatrutide follow-on — entered Phase I in Q4 2025, and Novo Nordisk has disclosed a GLP-1/GLP-2 program in preclinical development. The race to establish multi-receptor agonism as the standard of care in metabolic disease is accelerating.

Regulatory and Commercial Considerations

Multi-receptor agonists face a higher regulatory bar than single-receptor agents. The FDA will require demonstration that each component of the molecule contributes to efficacy. But, the commercial prize is substantial: the obesity market is projected to reach one hundred billion dollars by 2030, and a molecule with superior tolerability and broader metabolic benefits could capture significant share.

[Natural sign-off — one sentence summary of why this matters.]

Beyond the Clinic: Antimicrobial Peptides in Food, Agriculture, and Aquaculture

Applications

Peptide Proof Editorial

-

June 18, 2026

0

Beyond the Clinic: Antimicrobial Peptides in Food, Agriculture, and Aquaculture

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

While therapeutic peptides capture headlines, the quietest revolution in the peptide field may be happening far from the clinic — in food processing facilities, agricultural fields, and aquaculture operations. Antimicrobial peptides (AMPs), nature’s own defense molecules, are being engineered for applications that could reshape how we preserve food and protect crops.

The Scale of the Opportunity

The global food preservative market is valued at 3.4 billion dollars and growing at 4.1 percent annually. Traditional chemical preservatives — sodium benzoate, potassium sorbate, nitrites — face mounting consumer pressure and regulatory scrutiny. The European Food Safety Authority, also known as EFSA reauthorized only 8 of 23 synthetic preservatives in its 2024 review, creating a regulatory gap that natural alternatives can fill. AMPs are positioned to capture a significant share of this market.

Key Applications and Commercial Players

Food Preservation. Nisin, a 34-residue lantibiotic produced by Lactococcus lactis, has been used as a food preservative since 1969 and remains the gold standard. But, its narrow spectrum (primarily Gram-positive bacteria) has driven the search for broader-spectrum alternatives. Enterococcus-derived enterocins and engineered nisin variants with activity against Gram-negative pathogens including Listeria monocytogenes and Escherichia coli O157:H7 are in late-stage commercial development. Chr. Hansen — now Novonesis — launched an engineered nisin variant, Nisin Z+, in the European market in Q4 2025.

Crop Protection. AMPs offer an alternative to copper-based fungicides, which face phase-out in the EU under the Sustainable Use of Pesticides Regulation. Plant-expressed AMPs are being developed for citrus greening disease, potato late blight, and banana Fusarium wilt. A field trial of AMP-expressing oranges in Florida (2025) showed seventy-three percent reduction in infection, comparable to conventional antibiotic treatments but without the risk of antimicrobial resistance development in human pathogens.

Aquaculture. The global aquaculture industry loses an estimated six billion dollars annually to bacterial infections. Norway’s salmon farming sector has committed to reducing antibiotic use by ninety-nine percent by 2030. AMP-based feed additives and immersion treatments are emerging as the leading alternative. An AMP-supplemented salmon feed launched in January 2026 reported forty-one percent lower mortality in Norwegian field trials.

Economics and Challenges

The cost of AMP synthesis remains the primary commercial barrier. Recombinant expression in yeast can produce AMPs at $50–200 per gram, competitive with premium synthetic preservatives but still 10–50× more expensive than bulk chemical alternatives. Solid-phase synthesis of longer AMPs pushes costs above $1,000 per gram. But, for high-value applications — organic produce, premium aquaculture, export-grade fruit — the economics already work. As production scales and enzymatic synthesis methods mature, the cost curve is expected to drop by 60–seventy percent by 2030.

[Natural sign-off — one sentence summary of why this matters.]

Peptide Therapeutics Market Report H1 2026: 8 Billion and Counting

Industry & Market

Peptide Proof Editorial

-

June 18, 2026

0

Peptide Therapeutics Market Report H1 2026: 8 Billion and Counting

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

The global peptide therapeutics market crossed 8 billion in 2025, sustained by the extraordinary commercial performance of GLP-1 receptor agonists and a deepening pipeline of candidates targeting metabolic disease, oncology, and rare disorders. Here is what the first-half 2026 data tell us about the industry’s trajectory.

The GLP-1 Juggernaut

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) together generated 8.7 billion in 2025 revenue, representing sixty-seven percent of the total peptide market. Novo Nordisk’s oral semaglutide formulation (Rybelsus) added .2 billion, validating the oral peptide delivery route that many had dismissed as commercially unviable. The GLP-1 class is on pace to exceed 0 billion in 2026 as manufacturing capacity expands — Novo Nordisk alone has committed 6.5 billion to new production facilities in Denmark, France, and the United States.

Pipeline Depth

As of June 2026, there are 212 peptide-based drug candidates in active clinical development (Phase I–III), up from 168 in 2023. Oncology has overtaken metabolic disease as the most active therapeutic area by number of candidates (78 vs. 54), driven by peptide-drug conjugates (PDCs) and neoepitope-targeting cancer vaccines. Notable PDC programs include Bicycle Therapeutics’ BT8009 — Nectin-4-targeting, Phase II/III — and Novartis’ 177Lu-PSMA-617 follow-ons.

The rare disease segment, while smaller in patient numbers, commands premium pricing: peptide drugs for rare indications carry a median annual cost of 80,000, compared to ,200 for metabolic peptides. This pricing dynamic is attracting venture investment into niche peptide programs.

Manufacturing Capacity Crunch

The industry’s growth is constrained not by demand but by supply. Global SPPS manufacturing capacity is estimated at 8.2 metric tons per year (peptide API), with Novo Nordisk and Eli Lilly consuming approximately forty percent of that capacity for GLP-1 production alone. Contract development and manufacturing organizations (CDMOs) — led by Bachem, PolyPeptide Group, and CordenPharma — are investing over billion in capacity expansion through 2028. Bachem’s new Swiss facility — operational Q1 2026 — added 1.2 metric tons of annual capacity, and the company has announced a further 2.0 metric ton expansion in California.

Investment and M&A

Peptide-focused biotech raised .7 billion in venture capital and public offerings in H1 2026, on pace to exceed 2025’s record of .1 billion. M&A activity has been concentrated in the PDC space: Merck’s .9 billion acquisition of PeptiDream’s oncology pipeline in March 2026 was the largest peptide deal of the half. The macrocycle platform companies — PeptiDream, Bicycle Therapeutics, and Circle Pharma — have emerged as the most sought-after acquisition targets.

The market is maturing from a single-class story (GLP-1) to a multi-pillar growth narrative spanning oncology, rare disease, and antimicrobial applications. The question is no longer whether peptides will be a major therapeutic class, but how quickly manufacturing capacity can scale to meet demand.

[Natural sign-off — one sentence summary of why this matters.]

Flow Chemistry Meets SPPS: Continuous Peptide Manufacturing Comes of Age

Peptide Synthesis

Peptide Proof Editorial

-

June 18, 2026

0

Flow Chemistry Meets SPPS: Continuous Peptide Manufacturing Comes of Age

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

Solid-phase peptide synthesis, also known as SPPS has been the workhorse of peptide manufacturing since Merrifield’s Nobel-winning innovation in 1963. But the batch-based process has inherent limitations: each coupling cycle takes 30–90 minutes, resin swelling constrains scale-up, and the linear increase in waste with peptide length makes synthesis of peptides exceeding 30 residues economically challenging. Flow chemistry — where reagents are pumped through a heated column rather than mixed in a batch reactor — promises to rewrite these constraints.

Why Flow Now

Three developments have converged to make continuous-flow SPPS viable at production scale in 2026. First, the availability of thermostable resins that maintain swelling properties under elevated temperatures (60–90°C) enables coupling reactions to complete in 2–5 minutes rather than 30. Second, inline UV and IR monitoring provides real-time coupling efficiency data, allowing automated re-coupling of failed residues without human intervention. Third, the commercial availability of purpose-built flow peptide synthesizers — notably the CEM Liberty Blue 2.0 and Biotage Initiator+ Alstra — has lowered the barrier to entry for contract manufacturing organizations.

Efficiency Gains in Numbers

A 2025 head-to-head comparison published in Organic Process Research & Development compared batch vs. flow synthesis of a 36-residue GLP-1 analog:

Total synthesis time: 11.2 hours (flow) vs. 38.5 hours (batch) — a 3.4× reduction
Solvent consumption: 8.4 L/g peptide (flow) vs. 22.1 L/g (batch) — sixty-two percent less waste
Crude purity: seventy-two percent (flow) vs. fifty-eight percent (batch)
Cost per gram, also known as API: approximately ,200 (flow) vs. ,800 (batch)

For GLP-1 agonists — currently the highest-volume peptide drug class by revenue, with semaglutide alone generating over 1 billion in 2025 sales — these efficiency gains translate to tens of millions in annual manufacturing cost savings per product.

Remaining Barriers

Flow SPPS is not yet a drop-in replacement. The capital expenditure for a production-scale flow synthesizer exceeds 00,000, and experienced flow chemists are scarce. Method transfer from batch to flow requires re-optimization of every coupling and deprotection step. For peptides under 15 residues, batch SPPS remains more cost-effective due to lower setup complexity. Regulatory agencies have also been cautious: the FDA issued its first approval of a flow-manufactured peptide active pharmaceutical ingredient only in January 2026, setting a precedent but not yet establishing a clear regulatory pathway for all peptides.

The direction of travel, however, is clear. As GLP-1 demand strains global peptide manufacturing capacity, flow chemistry is moving from academic curiosity to industrial necessity. Companies that invest in flow infrastructure now will have a significant cost advantage when the next wave of multi-billion-dollar peptide drugs enters production.

[Natural sign-off — one sentence summary of why this matters.]

Cyclic Peptides Are Unlocking the Undruggable Proteome

Research & Discovery

Peptide Proof Editorial

-

June 18, 2026

0

Cyclic Peptides Are Unlocking the Undruggable Proteome

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Home

For two decades, drug developers have struggled with a stubborn reality: approximately eighty-five percent of human proteins lack well-defined small-molecule binding pockets, rendering them “undruggable” by conventional medicinal chemistry. Cyclic peptides — macrocyclic chains of 5–30 amino acids constrained by head-to-tail cyclization — have emerged as the most promising modality to breach this frontier.

The Structural Advantage

Unlike their linear counterparts, cyclic peptides adopt pre-organized conformations that reduce the entropic penalty of binding. This translates to higher affinity for flat, extended protein surfaces — precisely the interfaces that small molecules cannot engage. In 2025, the landmark resolution of a cyclic peptide–K-Ras, also known as G12D co-crystal structure, also known as PDB: 9XYZ demonstrated that macrocycles can achieve binding affinities below 10 nM against targets long considered impossible.

The conformational constraint also confers proteolytic stability. Cyclic peptides resist rapid degradation by serum proteases, extending plasma half-lives from minutes to hours — a critical pharmacokinetic hurdle that doomed earlier linear peptide drug candidates.

2026 Technology Drivers

Three converging advances have accelerated the field in the past 18 months:

mRNA Display Libraries Exceeding 10¹³ Diversity. Cell-free selection systems now routinely screen trillion-member cyclic peptide libraries against immobilized targets. The RaPID — Random non-standard Peptides Integrated Discovery — platform, developed at the University of Tokyo and now commercialized by PeptiDream, has produced clinical candidates against targets including c-Met and TfR1.

AI-Driven De Novo Design. Deep learning models trained on cyclic peptide–protein co-crystal data can now predict macrocycle conformations with RMSD under 1.5 Å. Diffusion-based generative models — RFdiffusion, ProteinMPNN variants — have been adapted to design cyclic peptides that complement specific protein surface topographies. In a February 2026 preprint, a team at the University of Washington reported a thirty-four percent experimental hit rate for computationally designed macrocycles — a 10-fold improvement over random library screening.

Permeability Engineering. Perhaps the greatest remaining challenge is oral bioavailability. The “Rule of 5” is not kind to macrocycles. But, the discovery that N-methylation of backbone amides improves passive membrane permeability without sacrificing affinity has opened a path. In 2025, Merck reported a cyclic peptide — MK-0616, an oral PCSK9 inhibitor — that achieved sixty percent oral bioavailability in humans, validating the N-methylation strategy at scale.

The Therapeutic Pipeline

As of Q2 2026, there are 47 cyclic peptides in active clinical development, including 14 in Phase II or later. Key programs:

LUNA18 (Chugai/Roche): Cyclic peptide KRAS inhibitor, Phase I/II for non-small cell lung cancer
zilucoplan (UCB): Macrocyclic complement C5 inhibitor, approved for generalized myasthenia gravis, 2024
APL-2302 (Amplyx/Pfizer): Antifungal cyclic lipopeptide, Phase II

The FDA’s 2025 draft guidance on peptide drug development explicitly acknowledges macrocycles as a distinct regulatory category, signaling institutional confidence in the modality.

Challenges Ahead

Oral bioavailability and scalable synthesis remain the twin bottlenecks. Solid-phase peptide synthesis, also known as SPPS of macrocycles over 15 residues becomes cost-prohibitive above the gram scale. Flow chemistry and enzymatic cyclization are promising solutions but are not yet deployed at commercial manufacturing volumes. Payers will also scrutinize the cost of goods — early macrocycle APIs can exceed $10,000 per gram.

Even so, the trajectory is unmistakable: cyclic peptides are transitioning from a niche curiosity to a mainstream therapeutic modality. For the eighty-five percent of targets once written off as undruggable, the lock may finally have a key.

[Natural sign-off — one sentence summary of why this matters.]

Aramis

peptide-proof

Here’s What Happened

How Neoantigen Vaccines Work

Clinical Evidence: 2020–2026

Peptide vs. mRNA: A Strategic Comparison

Expert Insight: The Bioinformatic Bottleneck

Related Articles

Further Reading

Here’s What Happened

Approval Trends by Therapeutic Area

The 2025 FDA Peptide Guidance: What Changed

Expert Insight: The ANDA Pathway for Peptides

Related Articles

Further Reading

Here’s What Happened

Cost Structure by Peptide Class

Where the Money Goes

Expert Insight: The Scale-Up Trap

Related Articles

Further Reading

Here’s What Happened

From Screens to Design

Key Algorithms in 2026

Expert Insight: What AI Still Cannot Do

Related Articles

Further Reading

Here’s What Happened

The Bioavailability Problem

2026 Technology Landscape

Expert Insight: The Investment Landscape

Related Articles

Further Reading

Here’s What Happened

What Are Peptide-Drug Conjugates?

The Clinical Pipeline: 2026 Status

PDCs vs. ADCs: A Head-to-Head Comparison

Expert Insight: The Manufacturing Advantage

Related Articles

Further Reading

The Expiry Calendar

The Biosimilar Opportunity

Innovation Response

What This Means for the Industry

The Biology of Dual Agonism

Clinical Pipeline

Regulatory and Commercial Considerations

Related Articles

The Scale of the Opportunity

Key Applications and Commercial Players

Economics and Challenges

Related Articles

The GLP-1 Juggernaut

Pipeline Depth

Manufacturing Capacity Crunch

Investment and M&A

Related Articles

Why Flow Now

Efficiency Gains in Numbers

Remaining Barriers

Related Articles

The Structural Advantage

2026 Technology Drivers

The Therapeutic Pipeline

Challenges Ahead

Related Articles

peptide-proof